ACLX
Arcellx, Inc.
$115.07
+0.00 (+0.00%)
At close · Apr 29
Market Cap
$6.73B
Shares
58,479,812
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$115.07
Open$115.07
Day$115.07–115.07
52W$47.86–115.13
Avg vol 30d1.5M
Short int1.8M · 3.1% float · 2.5d
Short vol49%
Last earningsOct 30, 2025
DataFeb 2022–Apr 2026
Filing10-K · Feb 26
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Feb 26, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Moderate
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+37%
above
Price vs 50-day avg
+3%
above
RSI (14)
80
overbought
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
+30%
trailing
YTD return
+76%
this year
Relative strength
+25%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $112 › 200d $84 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +96 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.08% of float · ▼ -20.7% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
241 holders — near 3-yr high, broad support
Fundamentals
Revenue growth
−79%
Y/Y
EPS growth
−104%
Y/Y
Free cash flow
$-212.6M
Balance sheet
$80.3M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
0.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+37%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
80
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $112 › 200d $84 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +96 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.08% of float · ▼ -20.7% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
241 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $48
Now $115 · 100%
52-wk high $115
vs 200-day avg +37%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ACLX
this stock
Arcellx, Inc.
|
$6.73B | +76.5% | -79.4% | — | 3.1% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ACLX | +0.1% | +0.2% | +30.5% | +0.2% | +76.5% |
| SPY | +0.1% | +9.4% | +5.4% | +9.4% | +4.4% |
| vs SPY | +0.0% | -9.2% | +25.1% | -9.2% | +72.1% |